Bevacizumab and Radiation Therapy for Sarcomas

Inclusion Criteria: * Primary soft tissue sarcoma (STS) or an isolated local recurrence of STS. Open incisional biopsy or core biopsies should be performed within 8 weeks prior to registration * Tumor grade of intermediate or high grade * Tumor must be located on the upper extremity, the lower extremity, trunk, retroperitoneum, or pelvis * Primary tumors must be \> 5.0cm in maximal diameter and local recurrence can be any size * 18 years of age or older * Zubrod performance status of 0-2 * Adequate organ and marrow function Exclusion Criteria: * Metastatic disease * Pregnant or lactating women * HIV positive patients * Prior treatment with radiation, chemotherapy or biotherapy for this tumor * History or evidence of central nervous system (CNS) disease * Serious, non-healing wound, ulcer, or bone fracture * Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year * History of stroke within the past 6 months * Major surgical procedure or significant traumatic injury within 28 days * Current or recent (within 10 days) use of full-dose oral or parenteral anticoagulants or thrombolytic agents. * Presence of bleeding diathesis or coagulopathy * Proteinuria at baseline or clinically significant impairment of renal function * History of abdominal fistula, gastrointestinal perforation, or inta-abdominal abscess within the past 6 months * Documented history of uncontrolled seizures * Grade 2 or greater sensory neuropathy based upon the NCI CTCAE, version 3.0 * Known history of deep vein thrombosis or pulmonary embolus * Known hypercoagulable disorder * History of hepatic cirrhosis or current hepatic dysfunction